

Taipei Veterans General Hospital Signs First Overseas Memorandum of Understanding with NYU Langone Health Strengthening Cancer Treatment Collaboration and Sharing Research Outcomes

Taipei Veterans General Hospital (TVGH) and NYU Langone Health held a collaboration and exchange meeting today (March 13, 2025) to deepen cooperation in medical education, clinical research, and specialized medical fields, with a particular focus on cancer treatment. This partnership was actively facilitated by Mr. Andre J.L. Koo, a board member of NYU. TVGH Superintendent Dr. Wei-Ming Chen and NYU Langone Health CEO and NYU Grossman School of Medicine Dean Dr. Robert I. Grossman jointly signed the Memorandum of Understanding (MOU).

To further enhance cooperation in pancreatic cancer treatment, a joint unveiling ceremony was held at the TVGH's Heavy Ion Therapy Center. This marks the launch of a collaborative heavy ion therapy program aimed at developing new treatment models, facilitating patient referrals to TVGH for treatment, and sharing treatment experiences and research findings. This initiative opens a new chapter in international medical collaboration.

NYU Langone Health is one of the world's leading medical institutions, renowned for its clinical and research excellence. This year, both NYU Langone Health and TVGH were ranked among the Top 250 Global Best Hospitals in 2025 by Newsweek. Superintendent Wei-Ming Chen emphasized that this exchange conference provided a valuable international collaboration platform and symbolized a stronger partnership in the medical field. Through this partnership, both institutions will work together to enhance cancer clinical treatment quality and advance cutting-edge medical technologies and research on a global scale.

Since launching heavy ion cancer therapy in May 2024, TVGH has treated approximately 450 patients with promising results, especially in pancreatic cancer treatment, which has achieved groundbreaking advancements. This success has garnered significant attention from the NYU Langone Health Cancer Center, leading to multiple exchanges between the two institutions. Superintendent Chen expressed special gratitude to NYU board member Mr. Andre J.L. Koo for his instrumental role in facilitating this formal collaboration. Last October, Mr. Koo arranged a visit to TVGH for NYU President Dr. Linda G. Mills and other key leaders, which ultimately led to today's formal MOU signing by the Dean of NYU Grossman School of Medicine and a team of experts.

Dr. Robert I. Grossman is a prominent leader in global healthcare, serving as CEO of NYU Langone Health and Dean of NYU Grossman School of Medicine. He has spearheaded numerous medical innovations, including the establishment of an accelerated three-year MD program and the provision of full-tuition scholarships for medical students. His efforts have significantly expanded NYU

Langone's impact, making it one of the largest healthcare systems in the Northeastern United States. Additionally, Dr. Grossman is a pioneer in data-driven healthcare, focusing on improving patient outcomes and streamlining clinical workflows. In recognition of his contributions to medicine and medical education, NYU School of Medicine was officially renamed NYU Grossman School of Medicine in 2019.

During the exchange meeting, Dr. Grossman delivered a keynote speech titled "Leaders and Leadership." He was accompanied by several renowned experts. Dr. Elisabeth J. Cohen is a leading authority in ophthalmology. Dr. Alec Kimmelman is a distinguished expert in radiation oncology. Dr. Stacey C. Kimmelman is a well-known psychologist specializing in mental health research.

Dr. Grossman highlighted that this marks the first-ever overseas MOU signed by NYU Langone Health, reflecting its strong commitment to international collaboration. Moving forward, NYU Langone will refer patients to TVGH for advanced heavy ion radiation therapy and other cutting-edge treatments.

TVGH Vice Superintendent Dr. Wui-Chiang Lee expressed great honor in collaborating with a world-class medical center, emphasizing that this partnership represents a win-win strategy and a significant step toward global medical integration. Both institutions will deepen collaboration in medical education, research, and patient care, leveraging each other's expertise and resources to enhance healthcare quality and establish a more sustainable global health system.

TVGH is the first hospital outside Japan to offer heavy ion cancer therapy, committed to providing cancer patients with precise and effective treatment solutions while continuously advancing medical research, patient care, and clinical education. Through this MOU, TVGH and NYU Langone Health will work together to explore new frontiers in medical collaboration. Their joint efforts will focus on advancing cancer treatment, enhancing heavy ion radiation therapy technology and research, and strengthening clinical training and medical education. This partnership aims to improve global cancer treatment standards and promote medical excellence on an international scale.



Figure 1. Taipei Veterans General Hospital Signed First Overseas Memorandum of Understanding with NYU Langone Health



Figure 2. The joint unveiling ceremony was held at the TVGH's Heavy Ion Therapy Center



Figure 3. Visited TVGH's Heavy Ion Therapy Center



Figure 3. Group photo of all participants